Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bemiparin→

Bemiparin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9041-08-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Low-molecular-weight heparin (LMWH)indirect anticoagulant
Mechanism of action
Binds antithrombin and potentiates its inhibition of activated factor Xa, with a smaller effect on thrombin (factor IIa), thereby reducing thrombin generation and fibrin clot formation.
Indications / reported uses
  • Prevention of venous thromboembolic events in patients undergoing selected surgical procedures or immobilisation, according to local product authorisation
  • Treatment of established deep-vein thrombosis in selected jurisdictions and formulations; dose and duration are product-specific

Sources: NLM MeSH — Bemiparin · PubMed — Bemiparin pharmacology and clinical use · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bemiparin Environmental Risk Assessment (ERA) (the Bemiparin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.